SavedAdd your journal

Journals / Turkish Journal of Hematology / 2008 / Cilt: 25 - Sayı: 2

Talasemiye bağlı osteoporoz tedavisinde intermittent pamidronat infüzyonu: İki yıllık takip sonuçları

Treatment of thalassemia-induced osteoporosis with intermittent pamidronate infusions: Two-year follow up

Türkan PATIROĞLU
Altuner Yasemin TORUN
Mustafa KULA
Musa KARAKÜKCÜ
Pages
79–82
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In view of the present findings, longer follow-up studies to determine long-term treatment are fully warranted.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The purpose of this study was to evaluate the bone mineral density (BMD) in 23 patients aged 7-14 years with thalassemia major and to assess the alterations in bone density in a two-year follow-up study.
📊
Key Findings & Data:Method: BMD of the lumbar spine and femoral neck was determined by dual-energy X-ray absorptiometry (DXA) at baseline, after 12 months of treatment and two years later.
💡
Conclusion & Impact:Conclusion: In view of the present findings, longer follow-up studies to determine long-term treatment are fully warranted.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Femur boynu · Osteoporoz · Absorptiyometri

Abstract

Objective: The purpose of this study was to evaluate the bone mineral density (BMD) in 23 patients aged 7-14 years with thalassemia major and to assess the alterations in bone density in a two-year follow-up study. Method: BMD of the lumbar spine and femoral neck was determined by dual-energy X-ray absorptiometry (DXA) at baseline, after 12 months of treatment and two years later. Pamidronate treatment (15 mg/dose, every 3 months for 1 year) was given to 23 osteoporotic (Z score below -2.5) and osteopenic (Z score -1 to -2.5) patients. After 12 months of treatment, all patients received only calcium and vitamin D supplements. After the two years of follow-up, BMD of the lumbar spine and femur was measured using DXA. Result: Administration of pamidronate resulted in a significant increase in BMD of the femoral neck. Lumbar spine BMD after pamidronate treatment was slightly higher than at baseline, but this was statistically non-significant. After two years, femoral neck and lumbar BMD had significantly increased compared to baseline. Conclusion: In view of the present findings, longer follow-up studies to determine long-term treatment are fully warranted.

Özet

Bu çalışmanın amacı 7-14 yaşlarında Talasemi major tanısı alan 23 hastanın kemik mineral dansitesini ve iki yıllık takip sonrası kemik dansitesindeki değişiklikleri değerlendirmektir. Lumber vertebra ve femoral boyun KMD Dual enerji X-ray absorbsiyometri (DXA) ile başlangıçta, tedaviden 12 ay ve 2 yıl sonra değerlendirildi. Pamidronat tedavisi (15mg/doz, bir yıl süreyle 3 ayda bir) 23 osteoporotik (Z skoru –2,5 altında) ve osteopenik (Z skoru –1 ile –2,5 arası) hastaya verildi. Tedaviden 12 ay sonra tüm hastalara sadece kalsiyum ve vitamin D verildi. İki yıl sonra lumber vertebra ve femur KMD’si DXA ile ölçüldü. Pamidronat verilmesi femur boyun KMD’sinde önemli bir artış sağladı. Lumber vertebra KMD’si pamidronat grubunda başlangıç grubuna göre hafif yüksekti ama bu istatistiksel olarak anlamlı değildi. İki yıl sonra femur boynu ve lumber vertebra KMD’sinde artış vardı. Bu bulgular doğrultusunda, uzun dönem tedaviyi belirlemek için daha uzun dönem takip çalışmalarına ihtiyaç vardır.

🔖

Cite This Article

PATIROĞLU, T., TORUN, A. Y., KULA, M., KARAKÜKCÜ, M. (2008). Talasemiye bağlı osteoporoz tedavisinde intermittent pamidronat infüzyonu: İki yıllık takip sonuçları. Turkish Journal of Hematology, Cilt: 25 - Sayı: 2, 79–82. https://ajindex.com/articles/413035

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353:1135-46
  2. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004;127:127-39
  3. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B. High incidence of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998;11:975-7
  4. Lala R, Chiabotto P, Di Stefano M, Isaia GC, Garofalo F, Piga A. Bone density and metabolism in thalassaemia. J Pediatr Endocrinol Metab 1998;11:785-90
  5. Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L, Gasparini P, Siciliani MC, Iolascon A. Osteoporosis in betathalassaemia major patients: analysis of the genetic background. Br J Haematol 2000;111:461-6
  6. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 2001;12:570-5
  7. De Virgiliis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988;113:661-9
  8. Roth C, Pekrun A, Bartz M, Jarry H, Eber S, Lakomek M, Schroter W. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr 1997;156:777-83
  9. Soliman AT, El Banna N, Abdel Fattah M, ElZalabani MM, Ansari BM. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism 1998;47:541-8
  10. Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, Hashemi R, Shamshirsaz AA, Aghakhani S, Homayoun H, Larijani B. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord 2003;3:4
  11. Fleisch H. Bisphosphonates in osteoporosis. Eur Spine J 2003;12:142-6
  12. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 2002;13:644-9
  13. Shaw NJ, Boivin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000;83:143-5
  14. Allgrove J. Use of bisphosphonates in children and adolescents. J Pediatr Endocrinol Metab 2002;15:921